NEWS DETAIL

Essai COMMODORE : Étude de suivi à long terme du géfitinib versus chimiothérapie de rattrapage dans la leucémie myéloïde aiguë récidivante/réfractaire porteuse de la mutation FLT3 – aml-hub.com

Essai COMMODORE : étude de suivi à long terme du géfitinib versus chimiothérapie de rattrapage dans la leucémie myéloïde aiguë récidivante/réfractaire porteuse de la mutation FLT3…

Informations médicales July 2, 2026

Contenu integral de l article

During the European Hematology Association (EHA) 2025 Congress, Jianxiang Wang presented the long-term follow-up data from the phase III COMMODORE trial of gilteritinib vs salvage chemotherapy in predominantly Asian patients with R/R FLT3m AML.

المنتجات المرتبطة بهذا المقال

تمت مطابقة هذه المنتجات تلقائيا استنادا الى عنوان المقال وملخصه ومحتواه.

الاسئلة الشائعة

Which products are related to this article?

The system matched these relevant products from the article content: لوسيوس جيلتيريتينيب – اشترِ عبر الإنترنت جيليدكس جيلتيريتينيب 40 ملغ.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.